GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists, and is focused on the the development and commercialization of cannabinoid delivery systems.
GCANRx has leveraged its licensed, patented technology platform, which has been successfully applied for drug delivery in other fields of use, for cannabis patients and consumers. GCANRx's conveyance platform can be utilized to deliver cannabis actives without requiring smoking, vaporizing, or other forms of administration.
The technology is versatile in that for the first time patients can receive personalized dosing, higher bioavailability, and a controlled rapid and/or slow release using just one, unobtrusive eluting oral patch. GCANRx's mission is to bring this technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers.